

.....
(Original Signature of Member)

119TH CONGRESS
2D SESSION

H. R. _____

To better coordinate Federal efforts to utilize advance technologies, such as artificial intelligence, to improve diagnoses, treatments, cures, and prevention strategies for pediatric cancer, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mr. MCCAUL introduced the following bill; which was referred to the
Committee on _____

A BILL

To better coordinate Federal efforts to utilize advance technologies, such as artificial intelligence, to improve diagnoses, treatments, cures, and prevention strategies for pediatric cancer, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE; TABLE OF CONTENTS.**

4 (a) SHORT TITLE.—This Act may be cited as the
5 “Ailani Myers Accelerating Innovation in Medicine to
6 Cure Kids with Cancer Act” or the “Ailani Myers AIM
7 to Cure Kids with Cancer Act”.

1 (b) TABLE OF CONTENTS.—The table of contents for
2 this Act is as follows:

Sec. 1. Short title; table of contents.

TITLE I—FEDERAL GOVERNMENT EFFORTS

Sec. 101. Coordination of Federal efforts.

TITLE II—DEPARTMENT OF HEALTH AND HUMAN SERVICES EFFORTS

Sec. 201. Childhood cancer data initiative.

Sec. 202. Harnessing innovation in artificial intelligence.

Sec. 203. Improving the data ecosystem, data sharing, and empowering patients.

Sec. 204. Reports.

TITLE III—GENERAL PROVISIONS

Sec. 301. Definitions.

Sec. 302. Privacy.

Sec. 303. Authorization of appropriations.

Sec. 304. Rule of construction.

3 **TITLE I—FEDERAL** 4 **GOVERNMENT EFFORTS**

5 **SEC. 101. COORDINATION OF FEDERAL EFFORTS.**

6 (a) IN GENERAL.—The President shall designate an
7 officer or employee of the Federal Government, or an of-
8 fice, council, or commission of the executive branch, to co-
9 ordinate Federal efforts to use advanced technologies, in-
10 cluding artificial intelligence, to improve the diagnosis,
11 treatment, and prevention of, and the development of
12 cures for, pediatric cancer. The officer, employee, office,
13 council, or commission so designated shall be known as
14 the Coordinator of AI Innovation (in this Act referred to
15 as the “Coordinator”).

1 (b) NOTIFICATION.—Not later than 30 days after
2 making a designation under subsection (a), the President
3 shall notify the appropriate committees of Congress of the
4 designation.

5 (c) DUTIES.—The Coordinator shall—

6 (1) coordinate and align the activities of rel-
7 evant Federal departments and agencies, in support
8 of the purposes specified in subsection (a), includ-
9 ing—

10 (A) the Department of Health and Human
11 Services, and the agencies and offices thereof,
12 including—

13 (i) the National Institutes of Health;

14 (ii) the Food and Drug Administra-
15 tion;

16 (iii) the Centers for Medicare & Med-
17 icaid Services;

18 (iv) the Advanced Research Projects
19 Agency for Health; and

20 (v) the Office of the National Coordi-
21 nator for Health Information Technology;

22 (B) the Department of Defense, including
23 the Defense Health Agency and the Congres-
24 sionally Directed Medical Research Programs;

25 (C) the Department of Energy;

- 1 (D) the Department of Veterans Affairs;
2 (E) the National Science Foundation;
3 (F) the National Institute of Standards
4 and Technology;
5 (G) the Office of Science and Technology
6 Policy; and
7 (H) such other Federal departments and
8 agencies as the Coordinator determines appro-
9 priate;
- 10 (2) facilitate, with respect to the Federal efforts
11 relating to pediatric cancer specified in subsection
12 (a), interagency coordination and collaboration
13 among Federal and non-Federal entities, such as pa-
14 tients, survivors, families, caregivers, researchers,
15 and entities funding research on pediatric cancer;
- 16 (3) align Federal data and artificial intelligence
17 policies affecting pediatric cancer research and care;
- 18 (4) consult with the Director of the National
19 Cancer Institute on matters affecting the CCDI; and
- 20 (5) support the Federal activities that advance
21 the purposes of this Act, including the activities of
22 the CCDI.

1 **TITLE II—DEPARTMENT OF**
2 **HEALTH AND HUMAN SERV-**
3 **ICES EFFORTS**

4 **SEC. 201. CHILDHOOD CANCER DATA INITIATIVE.**

5 (a) IN GENERAL.—The NCI Director shall carry out
6 the CCDI to collect, generate, standardize, link, and share
7 data with respect to individuals who are diagnosed with
8 cancer as a child, adolescent, or young adult in the United
9 States, regardless of the age of the individual on the date
10 such data is collected, regardless of where such individual
11 receives care, in order to improve outcomes for individuals
12 with such cancers, including with respect to prevention,
13 diagnosis, treatment, quality of life, and survivorship.

14 (b) COMPONENTS.—In carrying out subsection (a),
15 the NCI Director—

16 (1) shall support, at a minimum—

17 (A) molecular characterization of pediatric
18 cancers, including through the initiative known
19 as the Molecular Characterization Initiative of
20 the CCDI, and the sharing of the results of
21 such characterization to inform diagnosis and
22 treatment;

23 (B) the generation, analysis, and sharing
24 of data produced by non-invasive clinically vali-
25 dated technologies, software, and artificial intel-

1 ligence tools, including molecular testing and
2 functional precision medicine approaches, to in-
3 form diagnosis and treatment;

4 (C) data platforms, catalogs, and tools that
5 enable researchers and clinicians to find, access,
6 integrate, analyze, and share pediatric cancer
7 data, including the network of such platforms
8 and tools known as the CCDI Data Ecosystem;

9 (D) the collection and study of data on pe-
10 diatric cancers, including rare pediatric cancers;

11 (E) the aggregation and linkage of clinical,
12 research, and population-based data for sec-
13 ondary use, including through the registry
14 known as the National Childhood Cancer Reg-
15 istry; and

16 (F) the development of data standards and
17 infrastructure necessary to carry out subpara-
18 graphs (A) through (D); and

19 (2) may support such other activities as the
20 NCI Director determines appropriate to carry out
21 subsection (a).

22 (c) DIRECTOR OF THE CCDI.—The Secretary, on the
23 recommendation of the NCI Director, shall designate a Di-
24 rector of the Childhood Cancer Data Initiative (in this Act
25 referred to as the “CCDI Director”), who shall—

1 (1) be an individual with demonstrated sci-
2 entific expertise in pediatric oncology, biomedical
3 data science, or a related field;

4 (2) provide scientific and programmatic leader-
5 ship for the CCDI, including the components de-
6 scribed in subsection (b) and the artificial intel-
7 ligence activities described in section 202;

8 (3) coordinate the activities of the CCDI with
9 other Federal departments and agencies and with
10 non-Federal partners; and

11 (4) report to the NCI Director.

12 **SEC. 202. HARNESSING INNOVATION IN ARTIFICIAL INTEL-**
13 **LIGENCE.**

14 (a) IN GENERAL.—The NCI Director shall support,
15 in coordination with the Coordinator, the development and
16 application of artificial intelligence to accelerate progress
17 in pediatric cancer research and care, including through
18 the CCDI.

19 (b) DATA READINESS.—In carrying out subsection
20 (a), the NCI Director shall—

21 (1) expand and improve the artificial intel-
22 ligence readiness of the data platforms and tools of
23 the CCDI Data Ecosystem;

1 (2) consolidate and harmonize data from mul-
2 multiple sources to enable such data to be analyzed
3 using artificial intelligence; and

4 (3) develop data standards and technical ap-
5 proaches necessary for the use of artificial intel-
6 ligence with the data described in paragraphs (1)
7 and (2).

8 (c) RESEARCH AND ANALYSIS.—In carrying out sub-
9 section (a), the NCI Director shall support research on
10 pediatric cancer using artificial intelligence—

11 (1) to improve predictive modeling of patient
12 response, disease progression, and treatment tox-
13 icity;

14 (2) to derive novel diagnostic, prognostic, and
15 therapeutic biomarkers from molecular and imaging
16 data; and

17 (3) to carry out research projects, including
18 projects carried out at cancer centers designated by
19 the National Cancer Institute.

20 (d) CLINICAL TRIALS.—In carrying out subsection
21 (a), the Secretary shall support the use of multimodal data
22 and artificial intelligence to improve the design, partici-
23 pant recruitment and selection, administration, conduct,
24 and interpretation of clinical trials for medical products

1 intended to diagnose, treat, prevent, or cure pediatric can-
2 cer.

3 (e) RELATIONSHIP TO CCDI COMPONENTS.—Activi-
4 ties under this section shall supplement, and not supplant,
5 the components described in section 201(b).

6 (f) DISSEMINATION.—The Secretary shall make
7 methods, tools, data standards, and technical approaches
8 developed under this section available to other programs
9 of the National Cancer Institute, to other Federal depart-
10 ments and agencies, and, as appropriate, to the public.

11 **SEC. 203. IMPROVING THE DATA ECOSYSTEM, DATA SHAR-**
12 **ING, AND EMPOWERING PATIENTS.**

13 (a) INTEGRATION OF ARTIFICIAL INTELLIGENCE
14 INTO INTEROPERABILITY.—The Secretary of Health and
15 Human Services, acting through the National Coordinator
16 for Health Information Technology, shall ensure that arti-
17 ficial intelligence is appropriately integrated into inter-
18 operability activities carried out under title XXX of the
19 Public Health Service Act (42 U.S.C. 300jj et seq.), in
20 order to improve the potential for electronic health record
21 and claims data to inform private sector and academic re-
22 search and clinical trial design, while ensuring the privacy
23 of individually identifiable health information in accord-
24 ance with regulations promulgated under section 264(c)

1 of the Health Insurance Portability and Accountability
2 Act of 1996 (42 U.S.C. 1320d–2 note).

3 (b) INTEROPERABILITY STANDARDS.—Not later than
4 2 years after the date of the enactment of this Act, the
5 Secretary, acting through the National Coordinator for
6 Health Information Technology, shall finalize interoper-
7 ability standards for patient data to be used with artificial
8 intelligence that—

9 (1) appropriately account for structured and
10 unstructured data;

11 (2) enable safe and privacy-compliant exchanges
12 of data; and

13 (3) account for the needs of pediatric patients,
14 including pediatric cancer patients, as a priority use
15 case.

16 (c) APPLICABILITY.—The standards finalized under
17 subsection (b) shall be developed for application through-
18 out the Department of Health and Human Services and
19 shall not be limited in application to the CCDI or to the
20 National Cancer Institute.

21 (d) CONSULTATION AND PATIENT ENGAGEMENT.—
22 In carrying out this section, the Secretary, acting through
23 the National Coordinator for Health Information Tech-
24 nology, shall—

1 (1) consult with the Director, the CCDI Direc-
2 tor, patients and their families, health care pro-
3 viders, researchers, and developers of health infor-
4 mation technology;

5 (2) coordinate with the patient community to
6 ensure transparency and to establish mechanisms for
7 the sharing of data; and

8 (3) identify existing barriers to pediatric data
9 sharing and interoperability, in coordination with the
10 stakeholder community, and make recommendations
11 to address such barriers.

12 **SEC. 204. REPORTS.**

13 (a) INTERIM REPORT.—Not later than 180 days
14 after the date of the enactment of this Act, the Secretary
15 of Health and Human Services shall submit to the appro-
16 priate committees of Congress a report that—

17 (1) describes the progress made in imple-
18 menting this title;

19 (2) includes any interim findings of the Sec-
20 retary with respect to that implementation; and

21 (3) identifies any barriers to that implementa-
22 tion.

23 (b) ANNUAL REPORTS.—Not later than 1 year after
24 the date of the enactment of this Act, and annually there-
25 after through fiscal year 2031, the Secretary of Health

1 and Human Services shall submit to the appropriate com-
2 mittees of Congress a report that includes—

3 (1) a description of the activities carried out
4 under this title, including each component described
5 in section 201(b) and the artificial intelligence ac-
6 tivities described in section 202;

7 (2) the amounts expended on such activities;

8 (3) progress on data sharing, interoperability,
9 and privacy protections, including the status of the
10 interoperability standards required under section
11 203(b);

12 (4) the barriers identified in section 203(d)(3)
13 and the recommendations made to address such bar-
14 riers; and

15 (5) outcomes and measures of progress with re-
16 spect to the diagnosis, treatment, prevention, or cure
17 of pediatric cancer.

18 **TITLE III—GENERAL** 19 **PROVISIONS**

20 **SEC. 301. DEFINITIONS.**

21 In this Act:

22 (1) APPROPRIATE COMMITTEES OF CON-
23 GRESS.—The term “appropriate committees of Con-
24 gress” means—

1 (A) the Committee on Energy and Com-
2 merce of the House of Representatives;

3 (B) the Committee on Science, Space, and
4 Technology of the House of Representatives;

5 (C) the Committee on Health, Education,
6 Labor, and Pensions of the Senate; and

7 (D) the Committee on Commerce, Science,
8 and Transportation of the Senate.

9 (2) ARTIFICIAL INTELLIGENCE.—The term “ar-
10 tificial intelligence” has the meaning given such
11 term in section 238(g) of the John S. McCain Na-
12 tional Defense Authorization Act for Fiscal Year
13 2019 (Public Law 115–232).

14 (3) CCDI.—The term “CCDI” means the ini-
15 tiative known as the Childhood Cancer Data Initia-
16 tive.

17 (4) NCI DIRECTOR.—The term “NCI Director”
18 means the Director of the National Cancer Institute.

19 **SEC. 302. PRIVACY.**

20 Activities under this Act shall be carried out in a
21 manner consistent with applicable Federal and State laws
22 relating to the privacy of patient information, including
23 the regulations promulgated under section 264(e) of the
24 Health Insurance Portability and Accountability Act of
25 1996 (42 U.S.C. 1320d–2 note).

1 **SEC. 303. AUTHORIZATION OF APPROPRIATIONS.**

2 (a) IN GENERAL.—There are authorized to be appro-
3 priated to carry out this Act, other than section 201, such
4 sums as may be necessary for each of fiscal years 2027
5 through 2031.

6 (b) CCDI.—In addition to amounts authorized to be
7 appropriated under subsection (a), there are authorized to
8 be appropriated to carry out section 201 \$100,000,000 for
9 each of fiscal years 2027 through 2031.

10 **SEC. 304. RULE OF CONSTRUCTION.**

11 Nothing in this Act shall be construed to affect the
12 authority of the Secretary of Health and Human Services
13 or the Director of the National Cancer Institute under any
14 other provision of Federal law.